Opsens – 100,000 cases performed with the OptoWire
Quebec City, Quebec, May 20, 2020 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) reached an important milestone with more than 100,000 patients evaluated with the OptoWire™, a pressure guidewire for the diagnosis and treatment of coronary artery stenosis.
Accuracy in assessing the severity of coronary disease is critical and pressure guidewires have been shown to improve clinical outcomes when used to diagnose coronary disease. OpSens identified several unmet needs to bring to the market a modern pressure guidewire that meets cardiologists’ expectations for complex cases and their need for performance, reliability, and accuracy.
With its expertise and Fidela™, a second-generation fiber optic sensor, the Company has developed the OptoWire, the industry’s most effective pressure guidewire to diagnose and treat patients with coronary artery stenosis.
“Passing the 100,000 procedures mark is an accomplishment that highlights the quality of our product and the expanding need for the important clinical information provided by our technology. Our vision is to offer physicians the best product in all performance dimensions,“ said Louis Laflamme, OpSens’ President and CEO.
Since the launch of the first version of the OptoWire, OpSens has invested in research and development to improve its product and provide choice between hyperemic indices such as Fractional Flow Reserve (FFR), which is measured when the heart is stimulated by the injection of medication, and non-hyperemic indices such as diastolic pressure ratio (dPR), where accuracy is of utmost importance.
Now launching OpSens’ dPR with the OptoWire III, OpSens stands out by offering an efficient and cost-effective solution that makes a meaningful difference for patients with coronary disease as well as for healthcare professionals who expect to get the most from a single pressure guidewire.
Expanding our Technology into the Emerging Structural Heart Market
OpSens has developed innovative solutions for unmet clinical needs in coronary artery assessment. With that foundation, OpSens is pursuing an additional application for its technology in the high-growth Trans Aortic Valve Replacement (TAVR) market.
This procedure has shown exceptional impact for patients suffering from cardiac valve disease, being less traumatic and faster and easier to recover from than an aortic valve replacement through open-heart surgery (SAVR). Like percutaneous coronary interventions (PCI), major investments on device improvements have driven initial clinical outcome. The next phase of improvement will come from clinical practice and the development of adjunct devices, leading OpSens to develop a new device to improve clinical outcomes of TAVR and procedures’ efficiencies.
This new product should allow physicians to have continuous hemodynamic measurements to facilitate positioning and improve delivery of the transcatheter heart valve.
OpSens will benefit from the global sales and distribution networks it has developed, as well as of equipment already installed in cathlabs all around the world.
Exempted from the province of Quebec’s order to close non-essential businesses, OpSens has continued its operations without interruptions in the past few weeks. Adjustments have been made to ensure the safety of employees and of the supply and distribution chain. OpSens continued to respond continuously to customer demand.
OpSens focuses mainly on physiological measurements, such as FFR and dPR in interventional cardiology. OpSens offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 100,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.
OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of OpSens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact:
Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333
Robin Villeneuve, CPA, CA Chief Financial Officer, 418.781.0333